Further investigation and confirmation of these in silico data can shed light on the toxicity of mutant PFN-1 and may turn highly informative in pre-clinical studies for the development of a novel therapy for ALS patients with mutant PFN-1, as well as possible treatments to prevent in sALS cases. The gene discussed is PFN1; the disease is amyotrophic lateral sclerosis.